echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Nuocheng Jianhua's RTK inhibitor ICP-033 new drug research application was approved by the National Drug Administration...

    Nuocheng Jianhua's RTK inhibitor ICP-033 new drug research application was approved by the National Drug Administration...

    • Last Update: 2021-05-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Nuocheng Jianhua announced today that the company's new multi-target receptor tyrosine kinase (RTK) inhibitor ICP-033 New Drug Research (IND) application has been accepted by the National Medical Products Administration (NMPA).

    By acting on receptors such as discoid domain receptor 1/2 (DDR1/2), vascular endothelial growth factor receptor 2/3 (VEGFR 2/3), and platelet-derived growth factor receptor (PDGFR α/β) The amino acid kinase, ICP-033 can inhibit tumor angiogenesis, improve the tumor microenvironment, inhibit tumor growth, invasion and metastasis, thereby exerting target-specific anti-tumor effects.

    ICP-033 is a class 1 innovative drug of Nuocheng Jianhua with global independent intellectual property rights.
    It is planned to be used alone or/in combination with immunotherapy and other targeted drugs to treat liver cancer, renal cell carcinoma, colorectal cancer and other solid tumors.

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.